lundi 16 novembre 2026
RechercherExplore
Via News Knowledge File

Merck & Co., Inc.

organization80% conf.·synced Nov 16, 2026

Pharmaceutical company based in Rahway, NJ, known as MSD outside US and Canada

60
sourced metrics
676
relationships
20
stated objectives
2
Via News reports
Working data, not the finished story. This is what our AI has read and extracted from source documents so far. Before anything here becomes news, it is checked against the original source, fact-checked and put in context. Figures can be incomplete or wrongly labelled at this stage; our articles are the end product. How we source

Key metrics · each point sourced

Price 52 Week High
$156.45
Nov 13, 2026reference only
Stock Return Ytd
38.81%
Nov 13, 2026reference only
Price 52 Week Low
$92.86
Nov 13, 2026reference only
Market Cap
$364.26B
Nov 13, 2026reference only
Stock Price
$147.76
Nov 13, 2026reference only
Shares Outstanding
2.47Bshares
Jul 31, 2026reference only
Cost Of Revenue
$4.39B
Jun 30, 2026reference only
Cash
$6.85B
Jun 30, 2026reference only
Eps
-0.54USD per share
Jun 30, 2026reference only
Revenue
$16.61B
Jun 30, 2026reference only
Rd Expense
$9.74B
Jun 30, 2026reference only
Total Assets
$129.8B
Jun 30, 2026reference only
Stockholders Equity
$41.93B
Jun 30, 2026reference only
Net Income
-$1.33B
Jun 30, 2026reference only
Operating Cash Flow
$3.92B
Mar 31, 2026reference only
Capex
$991M
Mar 31, 2026reference only

Stated objectives

Enroll approximately 675 patients in KANDLELIT-007 Phase 3 trial

source
target: 675 patients stated

Evaluate progression-free survival as primary endpoint in PD-L1 TPS ≥1% patients in KANDLELIT-007

source
stated

Evaluate secondary endpoints including PFS in all patients, overall survival, objective response rate, duration of response, and safety in KANDLELIT-007

source
stated

Submit regulatory filings worldwide for KEYTRUDA + Padcev combination in muscle-invasive bladder cancer based on KEYNOTE-B15/EV-304 results

source
stated

Initiate second Merck-sponsored pivotal trial of zanzalintinib and belzutifan in RCC

source
stated

Full-year sales forecast

source
target: $64.5 billion to $65 billion by 2025-12-31 00:00:00stated

Full-year EPS forecast

source
target: $8.93 to $8.98 by 2025-12-31 00:00:00stated

Improving outcomes and addressing significant unmet needs for patients with hematologic neoplasms and malignancies

source
stated

Become the premier research-intensive biopharmaceutical company in the world

source
stated

Deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals

source
stated

Relationship graph · 676 connections

Developed by
275
Competes with
67
Employs
46
Acquired by
42
Partnered with
42
Regulates
29
Headquartered in
29
Covered by
28

Via News coverage

This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →